Accepted answer
2.4 mg a week is 125 mg a year and 10.4 mg in an average month — put every route on that denominator before comparing anything. Cost per milligram is the only figure that survives the comparison, because the presentations differ: a licensed pen prices a dose, a compounding pharmacy prices a vial, and a research supplier prices a mass. Divide each one's twelve-month cost by 125 mg and the three become the same number in the same unit. Then add what the cheapest route does not include — independent purity and content testing, the vials you discard, and the postage — because a route that needs testing to be trustworthy has that testing in its cost per milligram whether you account for it or not.
The honest answer is that the cheapest headline price is frequently not the cheapest outcome.
Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.
Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.
Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.
Decide whether you are optimising cost or confidence before you build the model.
edited 12 Jul 2026 by t_oyelaran — corrected a unit error in the worked example